HLA-DR Antibody (L243) - BSA Free

Human Leukocyte Antigen -DR isotype (HLA-DR) is a major histocompatibility complex (MHC) class II molecule expressed by antigen presenting cells (APCs) that plays a significant role in immune response (1). Class II molecules also include isoforms HLA-DP and -DQ (1,2). These type I membrane glycoproteins on APCs present peptides to helper T cells and T cell receptors on CD4+ cells (1). In humans, the genes encoding class II MHC proteins are located on chromosome 6p21, where HLA-DR is typically the most highly expressed, followed by HLA-DQ and then HLA-DP (3). Structurally, HLA-DR molecules are heterodimers consisting of an alpha chain subunit with an approximate theoretical molecular weight of 34 kDa and one of many approximately 30 kDa beta subunits (1-3). The alpha and beta genes are considered highly polymorphic with duplication resulting in nine DRB (beta subunit of HLA-DR) genes (DRB1-DRB9); though only DRB1, DRB3, DRB4, and DRB5 are considered functional (2,3). On the other hand, the alpha subunit is encoded by a single DRA gene (2,3). Studies focusing on the structural and biochemical properties of peptides that bind to HLA-DR molecules have helped contribute to subunit vaccine design and development (3).

Given the role in adaptive immunity, HLA-DR allele polymorphisms, gene misexpression, and dysfunction has been implicated in many diseases ranging from autoimmune disorders to cancer (2). HLA-DR is also a classical biomarker for disease, including sepsis where reduced expression of HLA-DR molecules on monocytes, as measured by flow cytometry, indicates diagnosis and prognosis (4,5). Immunosuppression observed with sepsis results in decreased surface expression of HLA-DR and concurrent increase in expression of programmed death 1 (PD-1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), and B and T lymphocyte attenuator (BTLA) (4). This altered expression results in poor T cell response and apoptosis, along with reduced interferon-gamma (IFN-gamma) production and increased pro-inflammatory cytokine release (4). Furthermore, the decrease in HLA-DR expression is also correlated with the decrease in CD14lowCD16+ inflammatory monocytes (5). Interestingly, COVID-19 patients also exhibit a reduction in HLA-DR that correlates with disease severity and immunosuppression (5).

References

1. Andersson G. (1998). Evolution of the human HLA-DR region. Frontiers in bioscience : a journal and virtual library. https://doi.org/10.2741/a317

2. Shiina, T., Hosomichi, K., Inoko, H., & Kulski, J. K. (2009). The HLA genomic loci map: expression, interaction, diversity and disease. Journal of human genetics. https://doi.org/10.1038/jhg.2008.5

3. Stern, L. J., & Calvo-Calle, J. M. (2009). HLA-DR: molecular insights and vaccine design. Current pharmaceutical design. https://doi.org/10.2174/138161209789105171

4. Zhuang, Y., Peng, H., Chen, Y., Zhou, S., & Chen, Y. (2017). Dynamic monitoring of monocyte HLA-DR expression for the diagnosis, prognosis, and prediction of sepsis. Frontiers in bioscience (Landmark edition). https://doi.org/10.2741/4547

5. Benlyamani, I., Venet, F., Coudereau, R., Gossez, M., & Monneret, G. (2020). Monocyte HLA-DR Measurement by Flow Cytometry in COVID-19 Patients: An Interim Review. Cytometry. Part A : the journal of the International Society for Analytical Cytology. https://doi.org/10.1002/cyto.a.24249

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 12 applications: B/N, ELISA, EM, FLISA, FLOW, Func, ICC/F, IF/IHC, IHC-Fr, IP, In vitro, WB.

Showing Publications 1 - 10 of 34. Show All 34 Publications. Collapse Publications.

Publications using NB100-77855	Applications	Species
Balmert SC, Ghozloujeh ZG, Carey CD et al. A microarray patch SARS-CoV-2 vaccine induces sustained antibody responses and polyfunctional cellular immunity iScience 2022-10-21 [PMID: 36062075]
Bhargavan B, Woollard SM, McMillan JE, Kanmogne GD CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice Molecular neurodegeneration 2021-11-22 [PMID: 34809709]
Mo Y, Cheung AKL, Liu Y et al. Imaging and analysis on the interaction between human antigen-pulsed V delta 2 T cells and antigen-specific CD4 T cells STAR Protocols 2021-06-01 [PMID: 33937873]
Liu L, Fang C, Fu W et al. Endothelial Cell-Derived IL-18 Released During Ischemia Reperfusion Injury Selectively Expands T Peripheral Helper Cells to Promote Alloantibody Production Circulation 2019-11-20 [PMID: 31744330]
Shibutani M, Maeda K, Nagahara H et al. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study. BMC Cancer 2018-04-03 [PMID: 29614981] (IF/IHC, Human)	IF/IHC	Human
Waghmare VN, Rong J, Rogers CJ et al. Comparative transmission genetics of introgressed chromatin in Gossypium (cotton) polyploids. American journal of botany 2017-07-19 [PMID: 27056931]
Kuo F, Histed S, Xu B et al. Immuno-PET Imaging of Tumor Endothelial Marker 8 (TEM8) Molecular Pharmaceutics 2015-07-01 [PMID: 24984190]
Oza V, Ashwell S, Almeida L et al. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas. Journal of medicinal chemistry 2012-10-01 [PMID: 22551018]
Petersen SH Odintsova E Haigh TA et al. The role of tetraspanin CD63 in antigen presentation via MHC class II. Eur J Immunol. 2011-09-01 [PMID: 21660937] (EM, Human)	EM	Human
Ivanov A Beers SA Walshe CA et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009-08-01 [PMID: 19620786] (Func, In vitro, Human)	Func, In vitro	Human
Apps R Murphy SP Fernando R et al. Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies. Immunology. 2009-05-01 [PMID: 19368562] (FLOW, Human)	FLOW	Human
Wahlstrom J Dengjel J Persson B et al. Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis. J Clin Invest. 2007-11-01 [PMID: 17975675]
Setterblad N Garban F Weigl R et al. Extracorporeal photophoresis increases sensitivity of monocytes from patients with graft-versus-host disease to HLA-DR-mediated cell death. Transfusion 2008-01-01 [PMID: 17900279] (Func, Human) Details: HLA DRB1 antibody (clone L243) was used at 10ug/ml conncentration for induction of cell death ex vivo on peripheral blood mononuclear cells /PBMNCs that were isolated from graft-versus-host disease/GVHD patients.	Func	Human
Dengjel J Schoor O Fischer R et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci U S A 2005-05-31 [PMID: 15894616]
Ovsyannikova IG Johnson KL Naylor S Poland GA. Identification of HLA-DRB1-bound self-peptides following measles virus infection. J Immunol Methods. 2005-02-01 [PMID: 15777939] (FLOW, Human)	FLOW	Human
Pashine A Busch R Belmares MP et al. Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity 2003-08-01 [PMID: 12932352] (FLOW)	FLOW
Gehring AJ Rojas RE Canaday DH et al. The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2. Infect Immun 2003-08-01 [PMID: 12874328] (B/N, Human)	B/N	Human
Hegde NR Tomazin RA Wisner TW et al. Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation. J Virol. 2002-11-01 [PMID: 12368336] (FLOW, Human) Details: HLA DRB1 antibody (clone L243) was used for FLOW analysis of His16 cells (derived by stable transfection of the human astroglioma cells U373-MG with the human class II transactivator CIITA) that were infected with Adtet-trans (120 PFU/cell) or AdtetUS2 and Adtet-trans (100 and 20 PFU/cell, respectively) for 18 hours. The antibody was used at 1:1000 dilution with 1 hour 4C incubation and detected using goat anti-mouse FITC conjugated secondary antibody on FACSCalibur flow cytometer.	FLOW	Human
Patil NS Pashine A Belmares MP et al. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles. J Immunol 2001-12-15 [PMID: 11739539] (FLOW, IP)	FLOW, IP
Kostelny SA Link BK Tso JY et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 2001-08-15 [PMID: 11477560] (ELISA, Func, Human) Details: pan-HLA-DR antibody clone L243 was used for induction of apoptosis in cultured Raji cells (Figure 8). Clone L243 of anti-HLA-DR was used as developing antibody with Hu1D10 (capturing antibody) for ELISA assays on the Raji cell lysate.	ELISA, Func	Human
Doebele RC Busch R Scott HM et al. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity 2000-10-01 [PMID: 11070170] (ELISA, FLOW, WB)	ELISA, FLOW, WB
Bainbridge DR Ellis SA Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol. 2000-08-01 [PMID: 10996380] (FLOW, Human)	FLOW	Human
van Ham M van Lith M Lillemeier B et al. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J Exp Med 2000-04-03 [PMID: 10748231] (FLOW, ELISA, Human)	FLOW, ELISA	Human
Texier C Pouvelle S Busson M et al. HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000-03-15 [PMID: 10706708] (FLISA)	FLISA
Bertho N Drenou B Laupeze B et al. HLA-DR-mediated apoptosis susceptibility discriminates differentiation stages of dendritic/monocytic APC. J Immunol 2000-03-01 [PMID: 10679073] (Func, Human)	Func	Human
Appel H Gauthier L Pyrdol J Wucherpfennig KW. Kinetics of T-cell receptor binding by bivalent HLA-DR. Peptide complexes that activate antigen-specific human T-cells. J Biol Chem 2000-01-07 [PMID: 10617620] (Human) Details: HLA-DR antibody clone L24 (specific for the assembled HLA-DR heterodimer) was used for affinity chromatography for purification of secreted soluble HLA-DR2 molecules from Drosophila melanogaster S2 cell line which was transfected with plasmid carrying DRa and DRb constructs as well as vector pH8CO.		Human
Hohn H Pilch H Gunzel S et al. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol 1999-11-15 [PMID: 10553103] (FLOW, Func, B/N, Human)	FLOW, Func, B/N	Human
Schick MR Levy S. The TAPA-1 molecule is associated on the surface of B cells with HLA-DR molecules. J Immunol. 1993-10-15 [PMID: 8409388] (IP, Human)	IP	Human
Chicz RM Urban RG Gorga JC et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993-07-01 [PMID: 8315383] (B/N)	B/N
Ulvestad E Williams K Bo L, . HLA class II molecules (HLA-DR, -DP, -DQ) on cells in the human CNS studied in situ and in vitro. Immunology 1994-08-01 [PMID: 7835916] (Func, IHC-Fr, ICC/F, Human)	Func, IHC-Fr, ICC/F	Human
Chen YX Evans RL Pollack MS et al. Characterization and expression of the HLA-DC antigens defined by anti-Leu 10. Hum Immunol. 1984-08-01 [PMID: 6332101] (FLOW, IHC-Fr, Human) Details: HLA-DR antibody (clone L243) was used for Flow analysis of human peripheral blood mononuclear cells (Figure 1) and for immunoperoxidase staining of frozen sections (IHC-Fr) from human tonsil and lymph node (Figure 3).	FLOW, IHC-Fr	Human
Robbins PA Evans EL Ding AH et al. Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes. Hum Immunol. 1987-04-01 [PMID: 3494718] (IP, Human)	IP	Human
Kabelitz D Janssen O. Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression. Cell Immunol 1989-04-15 [PMID: 2467753] (In vitro, Func, Human) Details: HLA DRB1 antibody (clone L243) was used for inhibiting the in vitro proliferation of Epstein-Barr virus-transformed human lymphoblastoid cell lines.	In vitro, Func	Human
Herman A Labrecque N Thibodeau J et al. Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR. Proc Natl Acad Sci U S A. 1991-11-15 [PMID: 1946464] (FLOW, Human)	FLOW	Human
Show All 34 Publications. Collapse Publications.

Images	Ratings	Applications	Species	Date	Details
Enlarge	5 reviewed by: Verified Customer	Flow	Canine	05/18/2018	View Summary Application Flow Cytometry Sample Tested Whole blood cells Species Canine Lot A3 Comments Comments The whole blood cells were lysed to get rid of the RBC. The washed cell were then incubated with the Antibody. They were washed and then incubated with a conjugated secondary. Allowed to sit for 20mins and then washed again and read on the BD Fortessa.

Array NB100-77855

• HLA-DR Antibodies